GleamWall
中文EN

QNTM Quantum Biopharma Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1771885 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)-230.2%
Asset turnover—

Leverage & solvency

Liabilities / assets54.3%
Debt / equity0.00x
Current ratio1.07x
Interest coverage-96.81x

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q42025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q42024-12-312024Q32024-09-302024Q2*2024-06-302024Q1*2024-03-31
Income statement
Revenue————————
R&D expense$70,404$495,223$549,197$1.65M$4.28M$744,802$897,986$160,260
SG&A expense$1.37M$3.04M$3.31M$1.33M$1.93M$3.25M$2.31M$1.92M
Operating income-$2.37M-$4.68M-$4.85M-$3.40M-$6.24M-$4.18M-$3.46M-$2.26M
Interest expense-$72,637$91,570$116,962$22,168-$21,799$10,371$8,357$12,414
Net income—$0$0$0—-$3.83M$0$0
EBITDA-$2.24M-$4.53M-$4.71M-$3.27M-$6.13M-$4.06M-$3.32M-$2.14M
EPS (diluted)————————
Weighted avg. shares (diluted)—————917,84841.68M—
Banking
Net interest income-$22,285$100,420$90,733$67,216$132,075$163,868$104,424$172,524
Balance sheet
Cash & equivalents$1.91M$445,944$1.50M$3.52M$6.00M$3.12M$3.31M$1.33M
Short-term investments$459,080$636,761$30,786$20,868$1.20M$3.49M$21,918—
Receivables—————$70,478——
Inventory$52,133$77,622$76,869$93,856$117,242———
Current assets$6.48M$9.34M$10.34M$9.93M$12.05M$13.84M$10.02M—
PP&E, netmay include right-of-use assets (IFRS)$67,029$69,485$72,034$74,397$76,894$64,909$64,873—
Intangibles$4.51M$4.62M$4.73M$4.83M$4.93M$5.04M$5.15M—
Total assets$11.16M$14.15M$15.30M$14.87M$17.12M$19.03M$15.25M—
Current liabilities$6.06M$6.65M$13.25M$10.34M$6.68M—$5.04M—
Total liabilities$6.06M$6.65M$13.25M$10.34M$6.68M$3.68M$5.04M—
Shareholders' equity$6.92M$8.65M$3.76M$5.73M$11.48M$16.29M$10.96M$11.51M
Cash flow statement
Operating cash flow-$305,598-$1.72M-$1.95M-$4.26M-$835,762-$3.46M-$606,482-$1.97M
Investing cash flow$350,650$408,419-$1.36M-$1.35M$1.24M-$3.46M$738,222-$22,140
Financing cash flow$1.41M$261,425$1.29M$3.13M$2.47M$6.74M$1.84M$568,719
Depreciation & amortization$129,371$145,336$141,383$129,690$112,803$120,814$136,813$120,141
Stock-based compensation$808,452$996,194$849,584$291,272-$82,477$65,424$111,524$57,743

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.